2. Anti-infection
  3. Antibiotic Bacterial
  4. Finafloxacin

Finafloxacin is an orally active fourth-generation fluoroquinolone broad-spectrum antibiotic. Finafloxacin exhibits stronger antibacterial activity in acidic pH environments and is not easily affected by bacterial multidrug efflux transporters. Finafloxacin is effective against a variety of extracellular pathogenic bacteria, and can also accumulate in macrophages, showing excellent antibacterial activity against intracellular Staphylococcus aureus, Listeria monocytogenes, Legionella pneumophila, Burkholderia pseudomallei, and other pathogens. Finafloxacin has been approved by the U.S. FDA for research on acute otitis externa mediated by Pseudomonas aeruginosa. Finafloxacin is also used in studies related to diseases such as melioidosis, inhalational tularemia, and inhalational plague.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Finafloxacin

Finafloxacin 화학구조

CAS No. : 209342-40-5

사이즈 가격 재고 수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 해외재고보유
Solution
10 mM * 1 mL in DMSO 해외재고보유
Solid
5 mg 해외재고보유
10 mg 해외재고보유
50 mg 해외재고보유
100 mg 해외재고보유
200 mg   견적 받기  
500 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 publication(s) in Google Scholar

Other Forms of Finafloxacin:

Finafloxacin Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Finafloxacin

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Finafloxacin is an orally active fourth-generation fluoroquinolone broad-spectrum antibiotic. Finafloxacin exhibits stronger antibacterial activity in acidic pH environments and is not easily affected by bacterial multidrug efflux transporters. Finafloxacin is effective against a variety of extracellular pathogenic bacteria, and can also accumulate in macrophages, showing excellent antibacterial activity against intracellular Staphylococcus aureus, Listeria monocytogenes, Legionella pneumophila, Burkholderia pseudomallei, and other pathogens. Finafloxacin has been approved by the U.S. FDA for research on acute otitis externa mediated by Pseudomonas aeruginosa. Finafloxacin is also used in studies related to diseases such as melioidosis, inhalational tularemia, and inhalational plague[1][2][3].

IC50 & Target

Quinolone

 

In Vitro

Finafloxacin (24 h; 48 h) inhibits growth of extracellular MSSA, CA-MRSA, HA-MRSA, VISA, L. monocytogenes, and L. pneumophila with MICs ranging from 0.01 mg/L (against L. pneumophila) to 16 mg/L (against a ciprofloxacin-resistant HA-MRSA isolate), and shows reduced susceptibility to NorA and Lde efflux mechanisms compared to ciprofloxacin[1].
Finafloxacin is bactericidal against intracellular L. monocytogenes in human THP-1 macrophages at neutral pH, but is less potent than ciprofloxacin[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Finafloxacin Related Antibodies
In Vivo

Finafloxacin (23.1 mg/kg; p.o.; every 8 h; 3-7 days) provides 100% survival when administered starting 24 h post inhalational F. tularensis challenge, and 50% survival when administered for 7 days starting 72 h postchallenge, with improved time to death compared to ciprofloxacin in the 3-day delayed regimen[3].
Finafloxacin (23.1 mg/kg; p.o.; every 8 h; 3-7 days) provides 100% survival when administered starting 24 h post inhalational Y. pestis challenge, and 80% to 100% survival when administered starting 38 h postchallenge[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 8 to 10 weeks old, inhalational challenge with Francisella tularensis SCHU S4)[3]
Dosage: 23.1 mg/kg
Administration: p.o.; every 8 h; 3 days; 7 days
Result: Provided 100% survival when treatment initiated at 24 h postchallenge, with 90% of mice showing no clinical signs of disease, no detectable bacteria in organs, and no histopathological changes typical of infection.
Increased time to death significantly compared to ciprofloxacin when treatment initiated at 72 h postchallenge for 3 days, with mice resolving clinical signs by day 7, relapsing by day 11, and succumbing by day 16.
Provided 50% survival when treatment initiated at 72 h postchallenge for 7 days, with all surviving mice having no detectable bacteria in organs and no histopathological changes typical of infection.
Caused less weight loss than ciprofloxacin in the 3-day 72 h postchallenge regimen, with differences identifiable at days 9 to 10 postchallenge.
분자량

398.39

화학식

C20H19FN4O4
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@]5([H])OCCN[C@@]5([H])C4)=C3C#N)C1=O)O
선적

Room temperature in continental US; may vary elsewhere.
보관
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
용액&용해도
In Vitro: 

DMSO : 6.4 mg/mL (16.06 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5101 mL 12.5505 mL 25.1010 mL
5 mM 0.5020 mL 2.5101 mL 5.0202 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • 몰농도 계산기

  • 농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
순도&문서

Purity: 98.75%

SDS (393 KB)

COA (251 KB) LCMS (87 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5101 mL 12.5505 mL 25.1010 mL 62.7526 mL
5 mM 0.5020 mL 2.5101 mL 5.0202 mL 12.5505 mL
10 mM 0.2510 mL 1.2551 mL 2.5101 mL 6.2753 mL
15 mM 0.1673 mL 0.8367 mL 1.6734 mL 4.1835 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Finafloxacin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Finafloxacin209342-40-5AntibioticBacterialLegionella pneumophilaPseudomonas aeruginosaBurkholderia pseudomalleiFrancisella tularensisTHP-1 macrophagesLdeStaphylococcus aureusNorAYersinia pestisListeria monocytogenesInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Finafloxacin
Cat. No.:
HY-13451
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.